Ubs Asset Management Americas Inc Travere Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 161,603 shares of TVTX stock, worth $3.81 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
161,603
Previous 163,175
0.96%
Holding current value
$3.81 Million
Previous $2.28 Million
23.36%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding TVTX
# of Institutions
213Shares Held
94.1MCall Options Held
1.2MPut Options Held
778K-
Black Rock Inc. New York, NY7.64MShares$180 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$174 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.74MShares$159 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$117 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$100 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.51B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...